A patient of coronary artery disease with diabetes mellitus has a history of myocardial infarction 2 months back. Lipid profile of the patient is serum triglyceride of 234 mg/dL, LDL 124 mg/dL and HDL 32 mg/dL. Which of the following drugs will you like to administer?
**Core Concept**
The patient has a history of myocardial infarction and coronary artery disease, indicating a need for aggressive lipid-lowering therapy. The lipid profile shows elevated triglycerides and LDL cholesterol, while HDL cholesterol is low. The patient's diabetes mellitus also requires careful management of lipid-lowering therapy to avoid worsening glycemic control.
**Why the Correct Answer is Right**
The patient's lipid profile indicates a need for a drug that can effectively lower both LDL and triglycerides. **Atorvastatin** is a statin that not only lowers LDL cholesterol but also has a mild triglyceride-lowering effect. Additionally, atorvastatin has a favorable effect on HDL cholesterol, which is beneficial in patients with coronary artery disease. The drug's mechanism of action involves inhibiting HMG-CoA reductase, a key enzyme in the cholesterol biosynthetic pathway.
**Why Each Wrong Option is Incorrect**
**Option A:** **Rosiglitazone** is a thiazolidinedione used in the management of type 2 diabetes mellitus. While it may improve insulin sensitivity, it is not a first-line treatment for dyslipidemia and may even worsen lipid profiles in some patients.
**Option B:** **Metformin** is a biguanide used in the management of type 2 diabetes mellitus. While it is effective in lowering glucose levels, it does not have a significant effect on lipid profiles and is not indicated for the treatment of dyslipidemia.
**Option C:** **Fenofibrate** is a fibrate that is effective in lowering triglycerides and increasing HDL cholesterol. However, it may not be the best choice in this patient, as it may worsen glycemic control and has a higher risk of myopathy compared to statins.
**Clinical Pearl / High-Yield Fact**
When choosing a lipid-lowering agent in patients with diabetes mellitus, it is essential to consider the potential impact on glycemic control and renal function. Statins, such as atorvastatin, are generally preferred over fibrates due to their more favorable side effect profile.
**Correct Answer:** C. Fenofibrate